Asthma remains one of the most prevalent chronic respiratory conditions, affecting millions globally with varying degrees of severity. Traditional management centered on inhaled corticosteroids and bronchodilators continues to play a pivotal role, yet advances in therapeutic strategies have expanded the horizon considerably. Biologic therapies targeting IgE, IL-5, IL-4, and IL-13 pathways are proving effective for patients with severe and refractory asthma, offering a precision medicine approach that reduces exacerbations and hospitalizations. Emerging inhaler technologies have also improved drug delivery efficiency while minimizing systemic side effects. Non-pharmacologic interventions such as allergen immunotherapy, breathing exercises, and patient education programs add to the arsenal of asthma treatment options, ensuring comprehensive disease control. The use of digital platforms for self-monitoring, adherence tracking, and teleconsultations further empowers patients, bridging gaps between clinical visits. Current research is exploring the influence of the microbiome, environmental exposures, and epigenetics on asthma phenotypes, opening new pathways for targeted therapies. The collective goal is to reduce disease burden, improve lung function, and enhance long-term outcomes through individualized, multidisciplinary care.
Title : Screening questionnaires for obstructive sleep apnea: An updated systematic review
Behzad Rahmati, Isfahan University of Medical Sciences, Iran (Islamic Republic of)
Title : Improving covid 19 candidate vaccine response through probiotics and micronutrient supplementation: Evaluating the role of TLR5
Zohre Eftekhari, Biotechnology Research Center, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Iatrogenic pneumothorax following nephrectomy: Case report
Chaimae Tahiri, National University Hospital Center of Fann, Senegal